-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Acorda Therapeutics, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from 2010 to 2023.
- Acorda Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending March 31, 2024 was -22.1 USD/shares, a 62.9% decline year-over-year.
- Acorda Therapeutics, Inc. Earnings Per Share, Diluted for the twelve months ending March 31, 2024 was -212 USD/shares, a 176% decline year-over-year.
- Acorda Therapeutics, Inc. annual Earnings Per Share, Diluted for 2023 was -204 USD/shares, a 212% decline from 2022.
- Acorda Therapeutics, Inc. annual Earnings Per Share, Diluted for 2022 was -65.2 USD/shares, a 566% decline from 2021.
- Acorda Therapeutics, Inc. annual Earnings Per Share, Diluted for 2021 was -9.79 USD/shares, a 20.5% increase from 2020.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Growth (%)